0001090872October 312021Q3false00010908722020-11-012021-07-31xbrli:shares00010908722021-08-26iso4217:USD0001090872us-gaap:ProductMember2021-05-012021-07-310001090872us-gaap:ProductMember2020-05-012020-07-310001090872us-gaap:ProductMember2020-11-012021-07-310001090872us-gaap:ProductMember2019-11-012020-07-310001090872us-gaap:ServiceOtherMember2021-05-012021-07-310001090872us-gaap:ServiceOtherMember2020-05-012020-07-310001090872us-gaap:ServiceOtherMember2020-11-012021-07-310001090872us-gaap:ServiceOtherMember2019-11-012020-07-3100010908722021-05-012021-07-3100010908722020-05-012020-07-3100010908722019-11-012020-07-31iso4217:USDxbrli:shares00010908722021-07-3100010908722020-10-3100010908722019-10-3100010908722020-07-310001090872us-gaap:CommonStockMember2021-04-300001090872us-gaap:AdditionalPaidInCapitalMember2021-04-300001090872us-gaap:RetainedEarningsMember2021-04-300001090872us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-04-300001090872us-gaap:ParentMember2021-04-300001090872us-gaap:RetainedEarningsMember2021-05-012021-07-310001090872us-gaap:ParentMember2021-05-012021-07-310001090872us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-05-012021-07-310001090872us-gaap:CommonStockMember2021-05-012021-07-310001090872us-gaap:AdditionalPaidInCapitalMember2021-05-012021-07-310001090872us-gaap:CommonStockMember2021-07-310001090872us-gaap:AdditionalPaidInCapitalMember2021-07-310001090872us-gaap:RetainedEarningsMember2021-07-310001090872us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-07-310001090872us-gaap:ParentMember2021-07-310001090872us-gaap:CommonStockMember2020-10-310001090872us-gaap:AdditionalPaidInCapitalMember2020-10-310001090872us-gaap:RetainedEarningsMember2020-10-310001090872us-gaap:AccumulatedOtherComprehensiveIncomeMember2020-10-310001090872us-gaap:ParentMember2020-10-310001090872us-gaap:RetainedEarningsMember2020-11-012021-07-310001090872us-gaap:ParentMember2020-11-012021-07-310001090872us-gaap:AccumulatedOtherComprehensiveIncomeMember2020-11-012021-07-310001090872us-gaap:CommonStockMember2020-11-012021-07-310001090872us-gaap:AdditionalPaidInCapitalMember2020-11-012021-07-310001090872us-gaap:CommonStockMember2020-04-300001090872us-gaap:AdditionalPaidInCapitalMember2020-04-300001090872us-gaap:RetainedEarningsMember2020-04-300001090872us-gaap:AccumulatedOtherComprehensiveIncomeMember2020-04-300001090872us-gaap:ParentMember2020-04-300001090872us-gaap:RetainedEarningsMember2020-05-012020-07-310001090872us-gaap:ParentMember2020-05-012020-07-310001090872us-gaap:AccumulatedOtherComprehensiveIncomeMember2020-05-012020-07-310001090872us-gaap:CommonStockMember2020-05-012020-07-310001090872us-gaap:AdditionalPaidInCapitalMember2020-05-012020-07-310001090872us-gaap:CommonStockMember2020-07-310001090872us-gaap:AdditionalPaidInCapitalMember2020-07-310001090872us-gaap:RetainedEarningsMember2020-07-310001090872us-gaap:AccumulatedOtherComprehensiveIncomeMember2020-07-310001090872us-gaap:ParentMember2020-07-310001090872us-gaap:CommonStockMember2019-10-310001090872us-gaap:AdditionalPaidInCapitalMember2019-10-310001090872us-gaap:RetainedEarningsMember2019-10-310001090872us-gaap:AccumulatedOtherComprehensiveIncomeMember2019-10-310001090872us-gaap:ParentMember2019-10-310001090872us-gaap:RetainedEarningsMember2019-11-012020-07-310001090872us-gaap:ParentMember2019-11-012020-07-310001090872us-gaap:AccumulatedOtherComprehensiveIncomeMember2019-11-012020-07-310001090872us-gaap:CommonStockMember2019-11-012020-07-310001090872us-gaap:AdditionalPaidInCapitalMember2019-11-012020-07-310001090872us-gaap:OtherAssetsMember2021-07-310001090872us-gaap:OtherAssetsMember2020-10-310001090872a:OtherAccruedAndLongTermLiabilitiesMember2021-07-310001090872a:OtherAccruedAndLongTermLiabilitiesMember2020-10-310001090872us-gaap:VariableInterestEntityNotPrimaryBeneficiaryMember2021-07-310001090872us-gaap:VariableInterestEntityNotPrimaryBeneficiaryMember2020-10-310001090872srt:AmericasMembera:LifeSciencesandAppliedMarketsMember2021-05-012021-07-310001090872srt:AmericasMembera:AgilentCrossLabMember2021-05-012021-07-310001090872srt:AmericasMembera:DiagnosticsAndGenomicsMember2021-05-012021-07-310001090872srt:AmericasMember2021-05-012021-07-310001090872srt:AmericasMembera:LifeSciencesandAppliedMarketsMember2020-05-012020-07-310001090872srt:AmericasMembera:AgilentCrossLabMember2020-05-012020-07-310001090872srt:AmericasMembera:DiagnosticsAndGenomicsMember2020-05-012020-07-310001090872srt:AmericasMember2020-05-012020-07-310001090872srt:EuropeMembera:LifeSciencesandAppliedMarketsMember2021-05-012021-07-310001090872srt:EuropeMembera:AgilentCrossLabMember2021-05-012021-07-310001090872srt:EuropeMembera:DiagnosticsAndGenomicsMember2021-05-012021-07-310001090872srt:EuropeMember2021-05-012021-07-310001090872srt:EuropeMembera:LifeSciencesandAppliedMarketsMember2020-05-012020-07-310001090872srt:EuropeMembera:AgilentCrossLabMember2020-05-012020-07-310001090872srt:EuropeMembera:DiagnosticsAndGenomicsMember2020-05-012020-07-310001090872srt:EuropeMember2020-05-012020-07-310001090872a:LifeSciencesandAppliedMarketsMembersrt:AsiaPacificMember2021-05-012021-07-310001090872srt:AsiaPacificMembera:AgilentCrossLabMember2021-05-012021-07-310001090872a:DiagnosticsAndGenomicsMembersrt:AsiaPacificMember2021-05-012021-07-310001090872srt:AsiaPacificMember2021-05-012021-07-310001090872a:LifeSciencesandAppliedMarketsMembersrt:AsiaPacificMember2020-05-012020-07-310001090872srt:AsiaPacificMembera:AgilentCrossLabMember2020-05-012020-07-310001090872a:DiagnosticsAndGenomicsMembersrt:AsiaPacificMember2020-05-012020-07-310001090872srt:AsiaPacificMember2020-05-012020-07-310001090872a:LifeSciencesandAppliedMarketsMember2021-05-012021-07-310001090872a:AgilentCrossLabMember2021-05-012021-07-310001090872a:DiagnosticsAndGenomicsMember2021-05-012021-07-310001090872a:LifeSciencesandAppliedMarketsMember2020-05-012020-07-310001090872a:AgilentCrossLabMember2020-05-012020-07-310001090872a:DiagnosticsAndGenomicsMember2020-05-012020-07-310001090872srt:AmericasMembera:LifeSciencesandAppliedMarketsMember2020-11-012021-07-310001090872srt:AmericasMembera:AgilentCrossLabMember2020-11-012021-07-310001090872srt:AmericasMembera:DiagnosticsAndGenomicsMember2020-11-012021-07-310001090872srt:AmericasMember2020-11-012021-07-310001090872srt:AmericasMembera:LifeSciencesandAppliedMarketsMember2019-11-012020-07-310001090872srt:AmericasMembera:AgilentCrossLabMember2019-11-012020-07-310001090872srt:AmericasMembera:DiagnosticsAndGenomicsMember2019-11-012020-07-310001090872srt:AmericasMember2019-11-012020-07-310001090872srt:EuropeMembera:LifeSciencesandAppliedMarketsMember2020-11-012021-07-310001090872srt:EuropeMembera:AgilentCrossLabMember2020-11-012021-07-310001090872srt:EuropeMembera:DiagnosticsAndGenomicsMember2020-11-012021-07-310001090872srt:EuropeMember2020-11-012021-07-310001090872srt:EuropeMembera:LifeSciencesandAppliedMarketsMember2019-11-012020-07-310001090872srt:EuropeMembera:AgilentCrossLabMember2019-11-012020-07-310001090872srt:EuropeMembera:DiagnosticsAndGenomicsMember2019-11-012020-07-310001090872srt:EuropeMember2019-11-012020-07-310001090872a:LifeSciencesandAppliedMarketsMembersrt:AsiaPacificMember2020-11-012021-07-310001090872srt:AsiaPacificMembera:AgilentCrossLabMember2020-11-012021-07-310001090872a:DiagnosticsAndGenomicsMembersrt:AsiaPacificMember2020-11-012021-07-310001090872srt:AsiaPacificMember2020-11-012021-07-310001090872a:LifeSciencesandAppliedMarketsMembersrt:AsiaPacificMember2019-11-012020-07-310001090872srt:AsiaPacificMembera:AgilentCrossLabMember2019-11-012020-07-310001090872a:DiagnosticsAndGenomicsMembersrt:AsiaPacificMember2019-11-012020-07-310001090872srt:AsiaPacificMember2019-11-012020-07-310001090872a:LifeSciencesandAppliedMarketsMember2020-11-012021-07-310001090872a:AgilentCrossLabMember2020-11-012021-07-310001090872a:DiagnosticsAndGenomicsMember2020-11-012021-07-310001090872a:LifeSciencesandAppliedMarketsMember2019-11-012020-07-310001090872a:AgilentCrossLabMember2019-11-012020-07-310001090872a:DiagnosticsAndGenomicsMember2019-11-012020-07-310001090872a:PharmaceuticalandBiopharmaceuticalMarketMember2021-05-012021-07-310001090872a:PharmaceuticalandBiopharmaceuticalMarketMember2020-05-012020-07-310001090872a:PharmaceuticalandBiopharmaceuticalMarketMember2020-11-012021-07-310001090872a:PharmaceuticalandBiopharmaceuticalMarketMember2019-11-012020-07-310001090872a:ChemicalandEnergyMarketMember2021-05-012021-07-310001090872a:ChemicalandEnergyMarketMember2020-05-012020-07-310001090872a:ChemicalandEnergyMarketMember2020-11-012021-07-310001090872a:ChemicalandEnergyMarketMember2019-11-012020-07-310001090872a:DiagnosticsandClinicalMarketMember2021-05-012021-07-310001090872a:DiagnosticsandClinicalMarketMember2020-05-012020-07-310001090872a:DiagnosticsandClinicalMarketMember2020-11-012021-07-310001090872a:DiagnosticsandClinicalMarketMember2019-11-012020-07-310001090872a:FoodMarketMember2021-05-012021-07-310001090872a:FoodMarketMember2020-05-012020-07-310001090872a:FoodMarketMember2020-11-012021-07-310001090872a:FoodMarketMember2019-11-012020-07-310001090872a:AcademiaandGovernmentMarketMember2021-05-012021-07-310001090872a:AcademiaandGovernmentMarketMember2020-05-012020-07-310001090872a:AcademiaandGovernmentMarketMember2020-11-012021-07-310001090872a:AcademiaandGovernmentMarketMember2019-11-012020-07-310001090872a:EnvironmentalandForensicsMarketMember2021-05-012021-07-310001090872a:EnvironmentalandForensicsMarketMember2020-05-012020-07-310001090872a:EnvironmentalandForensicsMarketMember2020-11-012021-07-310001090872a:EnvironmentalandForensicsMarketMember2019-11-012020-07-310001090872a:InstrumentationMember2021-05-012021-07-310001090872a:InstrumentationMember2020-05-012020-07-310001090872a:InstrumentationMember2020-11-012021-07-310001090872a:InstrumentationMember2019-11-012020-07-310001090872a:NonInstrumentationandOtherMember2021-05-012021-07-310001090872a:NonInstrumentationandOtherMember2020-05-012020-07-310001090872a:NonInstrumentationandOtherMember2020-11-012021-07-310001090872a:NonInstrumentationandOtherMember2019-11-012020-07-3100010908722020-04-302021-07-31xbrli:pure0001090872srt:MinimumMemberus-gaap:PerformanceSharesMember2020-11-012021-07-310001090872srt:MinimumMemberus-gaap:PerformanceSharesMember2021-05-012021-07-310001090872srt:MinimumMemberus-gaap:PerformanceSharesMember2020-05-012020-07-310001090872srt:MinimumMemberus-gaap:PerformanceSharesMember2019-11-012020-07-310001090872srt:MaximumMemberus-gaap:PerformanceSharesMember2020-11-012021-07-310001090872srt:MaximumMemberus-gaap:PerformanceSharesMember2021-05-012021-07-310001090872srt:MaximumMemberus-gaap:PerformanceSharesMember2019-11-012020-07-310001090872srt:MaximumMemberus-gaap:PerformanceSharesMember2020-05-012020-07-310001090872us-gaap:RestrictedStockUnitsRSUMember2019-11-012020-07-310001090872us-gaap:RestrictedStockUnitsRSUMember2020-11-012021-07-310001090872us-gaap:RestrictedStockUnitsRSUMember2020-05-012020-07-310001090872us-gaap:RestrictedStockUnitsRSUMember2021-05-012021-07-310001090872us-gaap:EmployeeStockOptionMember2020-11-012021-07-310001090872us-gaap:EmployeeStockOptionMember2020-05-012020-07-310001090872us-gaap:EmployeeStockOptionMember2021-05-012021-07-310001090872us-gaap:EmployeeStockOptionMember2019-11-012020-07-310001090872us-gaap:CostOfSalesMember2021-05-012021-07-310001090872us-gaap:CostOfSalesMember2020-05-012020-07-310001090872us-gaap:CostOfSalesMember2020-11-012021-07-310001090872us-gaap:CostOfSalesMember2019-11-012020-07-310001090872us-gaap:ResearchAndDevelopmentExpenseMember2021-05-012021-07-310001090872us-gaap:ResearchAndDevelopmentExpenseMember2020-05-012020-07-310001090872us-gaap:ResearchAndDevelopmentExpenseMember2020-11-012021-07-310001090872us-gaap:ResearchAndDevelopmentExpenseMember2019-11-012020-07-310001090872us-gaap:SellingGeneralAndAdministrativeExpensesMember2021-05-012021-07-310001090872us-gaap:SellingGeneralAndAdministrativeExpensesMember2020-05-012020-07-310001090872us-gaap:SellingGeneralAndAdministrativeExpensesMember2020-11-012021-07-310001090872us-gaap:SellingGeneralAndAdministrativeExpensesMember2019-11-012020-07-310001090872us-gaap:PublicUtilitiesInventoryTypeDomain2019-11-012020-10-310001090872us-gaap:PublicUtilitiesInventoryTypeDomain2020-11-012021-07-310001090872a:LtppMember2021-05-012021-07-310001090872a:LtppMember2020-05-012020-07-310001090872a:LtppMember2020-11-012021-07-310001090872a:LtppMember2019-11-012020-07-310001090872a:LTPPRSUMember2021-05-012021-07-310001090872a:LTPPRSUMember2020-05-012020-07-310001090872a:LTPPRSUMember2020-11-012021-07-310001090872a:LTPPRSUMember2019-11-012020-07-310001090872a:LifeSciencesandAppliedMarketsMember2020-10-310001090872a:DiagnosticsAndGenomicsMember2020-10-310001090872a:AgilentCrossLabMember2020-10-310001090872a:LifeSciencesandAppliedMarketsMember2021-07-310001090872a:DiagnosticsAndGenomicsMember2021-07-310001090872a:AgilentCrossLabMember2021-07-310001090872us-gaap:DevelopedTechnologyRightsMember2020-10-310001090872us-gaap:TrademarksMember2020-10-310001090872us-gaap:CustomerRelationshipsMember2020-10-310001090872a:ThirdPartyTechnologyandLicensesMember2020-10-310001090872a:TotalAmortizableIntangibleAssetsMember2020-10-310001090872us-gaap:InProcessResearchAndDevelopmentMember2020-10-310001090872us-gaap:DevelopedTechnologyRightsMember2021-07-310001090872us-gaap:TrademarksMember2021-07-310001090872us-gaap:CustomerRelationshipsMember2021-07-310001090872us-gaap:OrderOrProductionBacklogMember2021-07-310001090872a:ThirdPartyTechnologyandLicensesMember2021-07-310001090872a:TotalAmortizableIntangibleAssetsMember2021-07-310001090872us-gaap:InProcessResearchAndDevelopmentMember2021-07-310001090872a:ResolutionBioscienceIncMember2021-04-152021-04-150001090872a:ResolutionBioscienceIncMember2021-04-150001090872a:ResolutionBioscienceIncMember2021-05-012021-07-310001090872us-gaap:OtherCurrentLiabilitiesMembera:ResolutionBioscienceIncMember2021-07-310001090872us-gaap:OtherNoncurrentLiabilitiesMembera:ResolutionBioscienceIncMember2021-07-310001090872a:ResolutionBioscienceIncMember2020-11-012021-07-310001090872a:ResolutionBioscienceIncMember2021-07-310001090872us-gaap:OtherIntangibleAssetsMembera:ResolutionBioscienceIncMember2021-05-012021-07-310001090872us-gaap:GoodwillMembera:ResolutionBioscienceIncMember2021-05-012021-07-310001090872us-gaap:FairValueMeasurementsRecurringMemberus-gaap:OtherCurrentAssetsMember2021-07-310001090872us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel1Memberus-gaap:OtherCurrentAssetsMember2021-07-310001090872us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel2Memberus-gaap:OtherCurrentAssetsMember2021-07-310001090872us-gaap:FairValueMeasurementsRecurringMemberus-gaap:OtherCurrentAssetsMemberus-gaap:FairValueInputsLevel3Member2021-07-310001090872us-gaap:FairValueMeasurementsRecurringMemberus-gaap:OtherNoncurrentAssetsMember2021-07-310001090872us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel1Memberus-gaap:OtherNoncurrentAssetsMember2021-07-310001090872us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel2Memberus-gaap:OtherNoncurrentAssetsMember2021-07-310001090872us-gaap:FairValueMeasurementsRecurringMemberus-gaap:OtherNoncurrentAssetsMemberus-gaap:FairValueInputsLevel3Member2021-07-310001090872us-gaap:FairValueMeasurementsRecurringMember2021-07-310001090872us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel1Member2021-07-310001090872us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel2Member2021-07-310001090872us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel3Member2021-07-310001090872us-gaap:FairValueMeasurementsRecurringMemberus-gaap:OtherCurrentLiabilitiesMember2021-07-310001090872us-gaap:FairValueMeasurementsRecurringMemberus-gaap:OtherCurrentLiabilitiesMemberus-gaap:FairValueInputsLevel1Member2021-07-310001090872us-gaap:FairValueMeasurementsRecurringMemberus-gaap:OtherCurrentLiabilitiesMemberus-gaap:FairValueInputsLevel2Member2021-07-310001090872us-gaap:FairValueMeasurementsRecurringMemberus-gaap:OtherCurrentLiabilitiesMemberus-gaap:FairValueInputsLevel3Member2021-07-310001090872us-gaap:FairValueMeasurementsRecurringMemberus-gaap:OtherCurrentLiabilitiesMembera:ResolutionBioscienceIncMemberus-gaap:FairValueInputsLevel3Member2021-07-310001090872us-gaap:FairValueMeasurementsRecurringMemberus-gaap:OtherNoncurrentLiabilitiesMember2021-07-310001090872us-gaap:FairValueMeasurementsRecurringMemberus-gaap:OtherNoncurrentLiabilitiesMemberus-gaap:FairValueInputsLevel1Member2021-07-310001090872us-gaap:FairValueMeasurementsRecurringMemberus-gaap:OtherNoncurrentLiabilitiesMemberus-gaap:FairValueInputsLevel2Member2021-07-310001090872us-gaap:FairValueMeasurementsRecurringMemberus-gaap:OtherNoncurrentLiabilitiesMemberus-gaap:FairValueInputsLevel3Member2021-07-310001090872us-gaap:FairValueMeasurementsRecurringMemberus-gaap:OtherNoncurrentLiabilitiesMembera:ResolutionBioscienceIncMemberus-gaap:FairValueInputsLevel3Member2021-07-310001090872us-gaap:FairValueMeasurementsRecurringMemberus-gaap:OtherCurrentAssetsMember2020-10-310001090872us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel1Memberus-gaap:OtherCurrentAssetsMember2020-10-310001090872us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel2Memberus-gaap:OtherCurrentAssetsMember2020-10-310001090872us-gaap:FairValueMeasurementsRecurringMemberus-gaap:OtherCurrentAssetsMemberus-gaap:FairValueInputsLevel3Member2020-10-310001090872us-gaap:FairValueMeasurementsRecurringMemberus-gaap:OtherNoncurrentAssetsMember2020-10-310001090872us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel1Memberus-gaap:OtherNoncurrentAssetsMember2020-10-310001090872us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel2Memberus-gaap:OtherNoncurrentAssetsMember2020-10-310001090872us-gaap:FairValueMeasurementsRecurringMemberus-gaap:OtherNoncurrentAssetsMemberus-gaap:FairValueInputsLevel3Member2020-10-310001090872us-gaap:FairValueMeasurementsRecurringMember2020-10-310001090872us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel1Member2020-10-310001090872us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel2Member2020-10-310001090872us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel3Member2020-10-310001090872us-gaap:FairValueMeasurementsRecurringMemberus-gaap:OtherCurrentLiabilitiesMember2020-10-310001090872us-gaap:FairValueMeasurementsRecurringMemberus-gaap:OtherCurrentLiabilitiesMemberus-gaap:FairValueInputsLevel1Member2020-10-310001090872us-gaap:FairValueMeasurementsRecurringMemberus-gaap:OtherCurrentLiabilitiesMemberus-gaap:FairValueInputsLevel2Member2020-10-310001090872us-gaap:FairValueMeasurementsRecurringMemberus-gaap:OtherCurrentLiabilitiesMemberus-gaap:FairValueInputsLevel3Member2020-10-310001090872us-gaap:FairValueMeasurementsRecurringMemberus-gaap:OtherNoncurrentLiabilitiesMember2020-10-310001090872us-gaap:FairValueMeasurementsRecurringMemberus-gaap:OtherNoncurrentLiabilitiesMemberus-gaap:FairValueInputsLevel1Member2020-10-310001090872us-gaap:FairValueMeasurementsRecurringMemberus-gaap:OtherNoncurrentLiabilitiesMemberus-gaap:FairValueInputsLevel2Member2020-10-310001090872us-gaap:FairValueMeasurementsRecurringMemberus-gaap:OtherNoncurrentLiabilitiesMemberus-gaap:FairValueInputsLevel3Member2020-10-310001090872us-gaap:FairValueMeasurementsRecurringMember2021-05-012021-07-310001090872us-gaap:FairValueMeasurementsRecurringMember2020-11-012021-07-310001090872us-gaap:FairValueMeasurementsRecurringMember2020-05-012020-07-310001090872a:MeasurementInputAssetVolatilityMember2021-07-310001090872a:MeasurementInputRevenueVolatilityMembersrt:MinimumMember2021-07-310001090872srt:MaximumMembera:MeasurementInputRevenueVolatilityMember2021-07-3100010908722021-04-3000010908722020-04-300001090872us-gaap:FairValueMeasurementsNonrecurringMember2021-05-012021-07-310001090872us-gaap:FairValueMeasurementsNonrecurringMember2020-05-012020-07-310001090872us-gaap:FairValueMeasurementsNonrecurringMember2020-11-012021-07-310001090872us-gaap:FairValueMeasurementsNonrecurringMember2019-11-012020-07-310001090872us-gaap:DesignatedAsHedgingInstrumentMembera:SeniorNotes2022Memberus-gaap:TreasuryLockMemberus-gaap:CashFlowHedgingMember2012-07-010001090872a:SeniorNotes2022Member2021-01-212021-01-210001090872a:SeniorNotes2022Member2012-09-130001090872a:SeniorNotes2022Member2021-04-052021-04-05a:contracts0001090872us-gaap:InterestRateSwapMemberus-gaap:DesignatedAsHedgingInstrumentMembera:SeniorNotes2026Memberus-gaap:CashFlowHedgingMember2016-02-010001090872us-gaap:InterestRateSwapMemberus-gaap:DesignatedAsHedgingInstrumentMembera:SeniorNotes2026Memberus-gaap:CashFlowHedgingMember2016-09-142016-09-150001090872us-gaap:InterestRateSwapMemberus-gaap:DesignatedAsHedgingInstrumentMembera:SeniorNotes2026Memberus-gaap:CashFlowHedgingMember2021-07-310001090872a:SeniorNotes2029Memberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:TreasuryLockMemberus-gaap:CashFlowHedgingMember2019-08-160001090872a:SeniorNotes2029Memberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:TreasuryLockMemberus-gaap:CashFlowHedgingMember2019-09-062019-09-060001090872a:SeniorNotes2029Memberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:TreasuryLockMemberus-gaap:CashFlowHedgingMember2021-07-310001090872us-gaap:AccumulatedOtherComprehensiveIncomeMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:ForeignExchangeContractMemberus-gaap:NetInvestmentHedgingMember2021-05-012021-07-310001090872us-gaap:AccumulatedOtherComprehensiveIncomeMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:ForeignExchangeContractMemberus-gaap:NetInvestmentHedgingMember2020-11-012021-07-310001090872us-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:ForeignExchangeForwardMemberus-gaap:CashFlowHedgingMember2021-07-310001090872us-gaap:NondesignatedMemberus-gaap:ForeignExchangeForwardMember2021-07-310001090872us-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:ForeignExchangeForwardMemberus-gaap:NetInvestmentHedgingMember2021-07-310001090872currency:EURus-gaap:ShortMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:ForwardContractsMemberus-gaap:CashFlowHedgingMember2021-07-310001090872currency:EURus-gaap:ShortMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:NetInvestmentHedgingMemberus-gaap:ForwardContractsMember2021-07-310001090872currency:EURus-gaap:LongMemberus-gaap:NondesignatedMemberus-gaap:ForwardContractsMember2021-07-310001090872us-gaap:ShortMemberus-gaap:DesignatedAsHedgingInstrumentMembercurrency:GBPus-gaap:ForwardContractsMemberus-gaap:CashFlowHedgingMember2021-07-310001090872us-gaap:ShortMembercurrency:GBPus-gaap:NondesignatedMemberus-gaap:ForwardContractsMember2021-07-310001090872currency:CADus-gaap:ShortMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:ForwardContractsMemberus-gaap:CashFlowHedgingMember2021-07-310001090872currency:CADus-gaap:ShortMemberus-gaap:NondesignatedMemberus-gaap:ForwardContractsMember2021-07-310001090872us-gaap:ShortMemberus-gaap:DesignatedAsHedgingInstrumentMembercurrency:JPYus-gaap:ForwardContractsMemberus-gaap:CashFlowHedgingMember2021-07-310001090872us-gaap:ShortMembercurrency:JPYus-gaap:NondesignatedMemberus-gaap:ForwardContractsMember2021-07-310001090872us-gaap:LongMemberus-gaap:NondesignatedMembercurrency:DKKus-gaap:ForwardContractsMember2021-07-310001090872us-gaap:ShortMemberus-gaap:DesignatedAsHedgingInstrumentMembercurrency:KRWus-gaap:ForwardContractsMemberus-gaap:CashFlowHedgingMember2021-07-310001090872us-gaap:ShortMembercurrency:KRWus-gaap:NondesignatedMemberus-gaap:ForwardContractsMember2021-07-310001090872us-gaap:LongMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:ForwardContractsMembercurrency:SGDus-gaap:CashFlowHedgingMember2021-07-310001090872us-gaap:LongMemberus-gaap:NondesignatedMembercurrency:SGDus-gaap:ForwardContractsMember2021-07-310001090872us-gaap:ShortMemberus-gaap:NondesignatedMemberus-gaap:ForwardContractsMembercurrency:CHF2021-07-310001090872us-gaap:ShortMembercurrency:CNYus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:ForwardContractsMemberus-gaap:CashFlowHedgingMember2021-07-310001090872us-gaap:ShortMembercurrency:CNYus-gaap:NondesignatedMemberus-gaap:ForwardContractsMember2021-07-310001090872currency:SEKus-gaap:ShortMemberus-gaap:NondesignatedMemberus-gaap:ForwardContractsMember2021-07-310001090872us-gaap:ShortMembercurrency:TWDus-gaap:NondesignatedMemberus-gaap:ForwardContractsMember2021-07-310001090872us-gaap:ShortMemberus-gaap:NondesignatedMembercurrency:INRus-gaap:ForwardContractsMember2021-07-310001090872currency:BRLus-gaap:ShortMemberus-gaap:NondesignatedMemberus-gaap:ForwardContractsMember2021-07-310001090872us-gaap:ShortMemberus-gaap:NondesignatedMembercurrency:THBus-gaap:ForwardContractsMember2021-07-310001090872us-gaap:LongMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:ForwardContractsMembercurrency:XXXus-gaap:CashFlowHedgingMember2021-07-310001090872us-gaap:ShortMemberus-gaap:NondesignatedMemberus-gaap:ForwardContractsMembercurrency:XXX2021-07-310001090872us-gaap:ShortMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:ForwardContractsMemberus-gaap:CashFlowHedgingMember2021-07-310001090872us-gaap:ShortMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:NetInvestmentHedgingMemberus-gaap:ForwardContractsMember2021-07-310001090872us-gaap:LongMemberus-gaap:NondesignatedMemberus-gaap:ForwardContractsMember2021-07-310001090872us-gaap:OtherCurrentAssetsMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:ForeignExchangeContractMemberus-gaap:CashFlowHedgingMember2021-07-310001090872us-gaap:OtherCurrentAssetsMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:ForeignExchangeContractMemberus-gaap:CashFlowHedgingMember2020-10-310001090872us-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:ForeignExchangeContractMemberus-gaap:AccruedLiabilitiesMemberus-gaap:CashFlowHedgingMember2021-07-310001090872us-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:ForeignExchangeContractMemberus-gaap:AccruedLiabilitiesMemberus-gaap:CashFlowHedgingMember2020-10-310001090872us-gaap:OtherCurrentAssetsMemberus-gaap:ForeignExchangeContractMemberus-gaap:NondesignatedMember2021-07-310001090872us-gaap:OtherCurrentAssetsMemberus-gaap:ForeignExchangeContractMemberus-gaap:NondesignatedMember2020-10-310001090872us-gaap:ForeignExchangeContractMemberus-gaap:AccruedLiabilitiesMemberus-gaap:NondesignatedMember2021-07-310001090872us-gaap:ForeignExchangeContractMemberus-gaap:AccruedLiabilitiesMemberus-gaap:NondesignatedMember2020-10-310001090872us-gaap:AccumulatedOtherComprehensiveIncomeMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:ForeignExchangeContractMemberus-gaap:CashFlowHedgingMember2021-05-012021-07-310001090872us-gaap:AccumulatedOtherComprehensiveIncomeMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:ForeignExchangeContractMemberus-gaap:CashFlowHedgingMember2020-05-012020-07-310001090872us-gaap:AccumulatedOtherComprehensiveIncomeMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:ForeignExchangeContractMemberus-gaap:CashFlowHedgingMember2020-11-012021-07-310001090872us-gaap:AccumulatedOtherComprehensiveIncomeMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:ForeignExchangeContractMemberus-gaap:CashFlowHedgingMember2019-11-012020-07-310001090872us-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:ForeignExchangeContractMemberus-gaap:InterestExpenseMemberus-gaap:CashFlowHedgingMember2021-05-012021-07-310001090872us-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:ForeignExchangeContractMemberus-gaap:InterestExpenseMemberus-gaap:CashFlowHedgingMember2020-05-012020-07-310001090872us-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:ForeignExchangeContractMemberus-gaap:InterestExpenseMemberus-gaap:CashFlowHedgingMember2020-11-012021-07-310001090872us-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:ForeignExchangeContractMemberus-gaap:InterestExpenseMemberus-gaap:CashFlowHedgingMember2019-11-012020-07-310001090872us-gaap:CostOfSalesMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:ForeignExchangeContractMemberus-gaap:CashFlowHedgingMember2021-05-012021-07-310001090872us-gaap:CostOfSalesMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:ForeignExchangeContractMemberus-gaap:CashFlowHedgingMember2020-05-012020-07-310001090872us-gaap:CostOfSalesMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:ForeignExchangeContractMemberus-gaap:CashFlowHedgingMember2020-11-012021-07-310001090872us-gaap:CostOfSalesMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:ForeignExchangeContractMemberus-gaap:CashFlowHedgingMember2019-11-012020-07-310001090872us-gaap:AccumulatedOtherComprehensiveIncomeMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:ForeignExchangeContractMemberus-gaap:NetInvestmentHedgingMember2020-05-012020-07-310001090872us-gaap:AccumulatedOtherComprehensiveIncomeMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:ForeignExchangeContractMemberus-gaap:NetInvestmentHedgingMember2019-11-012020-07-310001090872us-gaap:NondesignatedMemberus-gaap:OtherNonoperatingIncomeExpenseMember2021-05-012021-07-310001090872us-gaap:NondesignatedMemberus-gaap:OtherNonoperatingIncomeExpenseMember2020-05-012020-07-310001090872us-gaap:NondesignatedMemberus-gaap:OtherNonoperatingIncomeExpenseMember2020-11-012021-07-310001090872us-gaap:NondesignatedMemberus-gaap:OtherNonoperatingIncomeExpenseMember2019-11-012020-07-310001090872us-gaap:CashFlowHedgingMember2021-05-012021-07-310001090872us-gaap:CostOfSalesMemberus-gaap:CashFlowHedgingMember2021-05-012021-07-310001090872us-gaap:PensionPlansDefinedBenefitMembercountry:US2021-05-012021-07-310001090872us-gaap:PensionPlansDefinedBenefitMembercountry:US2020-05-012020-07-310001090872us-gaap:ForeignPlanMemberus-gaap:PensionPlansDefinedBenefitMember2021-05-012021-07-310001090872us-gaap:ForeignPlanMemberus-gaap:PensionPlansDefinedBenefitMember2020-05-012020-07-310001090872country:USus-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember2021-05-012021-07-310001090872country:USus-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember2020-05-012020-07-310001090872us-gaap:PensionPlansDefinedBenefitMembercountry:US2020-11-012021-07-310001090872us-gaap:PensionPlansDefinedBenefitMembercountry:US2019-11-012020-07-310001090872us-gaap:ForeignPlanMemberus-gaap:PensionPlansDefinedBenefitMember2020-11-012021-07-310001090872us-gaap:ForeignPlanMemberus-gaap:PensionPlansDefinedBenefitMember2019-11-012020-07-310001090872country:USus-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember2020-11-012021-07-310001090872country:USus-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember2019-11-012020-07-310001090872us-gaap:PensionPlansDefinedBenefitMembercountry:US2021-07-310001090872us-gaap:ForeignPlanMemberus-gaap:PensionPlansDefinedBenefitMember2021-07-310001090872us-gaap:LineOfCreditMembera:A5YrUnsecuredCreditFacilityMember2019-03-132019-03-130001090872us-gaap:LineOfCreditMembera:A5YrUnsecuredCreditFacilityMember2019-03-130001090872us-gaap:LineOfCreditMembera:AdditionalIncrementalTermLoanFacilityMember2019-10-210001090872us-gaap:LineOfCreditMembera:A5YrUnsecuredCreditFacilityMember2021-04-210001090872us-gaap:LineOfCreditMembera:AdditionalIncrementalTermLoanFacilityMember2021-04-210001090872us-gaap:LineOfCreditMembera:A5YrUnsecuredCreditFacilityMember2021-07-310001090872us-gaap:LineOfCreditMembera:AdditionalIncrementalTermLoanFacilityMember2021-07-310001090872us-gaap:LineOfCreditMemberus-gaap:CommercialPaperMember2020-05-010001090872us-gaap:LineOfCreditMemberus-gaap:CommercialPaperMember2021-06-180001090872us-gaap:LineOfCreditMemberus-gaap:CommercialPaperMember2021-07-310001090872us-gaap:LineOfCreditMemberus-gaap:CommercialPaperMember2020-11-012021-07-310001090872a:SeniorNotes2022Member2021-07-310001090872a:SeniorNotes2022Member2020-10-310001090872a:SeniorNotes2023Member2021-07-310001090872a:SeniorNotes2023Member2020-10-310001090872a:SeniorNotes2026Member2021-07-310001090872a:SeniorNotes2026Member2020-10-310001090872a:SeniorNotes2029Member2021-07-310001090872a:SeniorNotes2029Member2020-10-310001090872a:SeniorNotes2030Member2021-07-310001090872a:SeniorNotes2030Member2020-10-310001090872a:SeniorNotes2031Member2021-07-310001090872a:SeniorNotes2031Member2020-10-310001090872a:SeniorNotes2022Member2012-09-132012-09-130001090872a:SeniorNotes2022Member2020-11-012021-07-310001090872a:SeniorNotes2031Member2021-03-122021-03-120001090872a:SeniorNotes2031Member2021-03-120001090872a:A2019RepurchaseProgramMember2018-11-190001090872a:A2019RepurchaseProgramMember2020-05-012020-07-310001090872a:A2019RepurchaseProgramMember2019-11-012020-07-310001090872a:A2019RepurchaseProgramMember2020-11-012021-07-310001090872a:A2019RepurchaseProgramMember2021-02-180001090872a:A2021RepurchaseProgramMember2021-02-180001090872a:A2021RepurchaseProgramMember2021-05-012021-07-310001090872a:A2021RepurchaseProgramMember2020-11-012021-07-310001090872a:A2021RepurchaseProgramMember2021-07-310001090872us-gaap:AccumulatedTranslationAdjustmentMember2021-04-300001090872us-gaap:AccumulatedDefinedBenefitPlansAdjustmentNetPriorServiceCostCreditMember2021-04-300001090872us-gaap:AccumulatedDefinedBenefitPlansAdjustmentNetUnamortizedGainLossMember2021-04-300001090872us-gaap:AociDerivativeQualifyingAsHedgeExcludedComponentParentMember2021-04-300001090872us-gaap:AccumulatedTranslationAdjustmentMember2021-05-012021-07-310001090872us-gaap:AccumulatedDefinedBenefitPlansAdjustmentNetPriorServiceCostCreditMember2021-05-012021-07-310001090872us-gaap:AccumulatedDefinedBenefitPlansAdjustmentNetUnamortizedGainLossMember2021-05-012021-07-310001090872us-gaap:AociDerivativeQualifyingAsHedgeExcludedComponentParentMember2021-05-012021-07-310001090872us-gaap:AccumulatedTranslationAdjustmentMember2021-07-310001090872us-gaap:AccumulatedDefinedBenefitPlansAdjustmentNetPriorServiceCostCreditMember2021-07-310001090872us-gaap:AccumulatedDefinedBenefitPlansAdjustmentNetUnamortizedGainLossMember2021-07-310001090872us-gaap:AociDerivativeQualifyingAsHedgeExcludedComponentParentMember2021-07-310001090872us-gaap:AccumulatedTranslationAdjustmentMember2020-10-310001090872us-gaap:AccumulatedDefinedBenefitPlansAdjustmentNetPriorServiceCostCreditMember2020-10-310001090872us-gaap:AccumulatedDefinedBenefitPlansAdjustmentNetUnamortizedGainLossMember2020-10-310001090872us-gaap:AociDerivativeQualifyingAsHedgeExcludedComponentParentMember2020-10-310001090872us-gaap:AccumulatedTranslationAdjustmentMember2020-11-012021-07-310001090872us-gaap:AccumulatedDefinedBenefitPlansAdjustmentNetPriorServiceCostCreditMember2020-11-012021-07-310001090872us-gaap:AccumulatedDefinedBenefitPlansAdjustmentNetUnamortizedGainLossMember2020-11-012021-07-310001090872us-gaap:AociDerivativeQualifyingAsHedgeExcludedComponentParentMember2020-11-012021-07-310001090872us-gaap:InterestExpenseMember2021-05-012021-07-310001090872us-gaap:InterestExpenseMember2020-05-012020-07-310001090872us-gaap:InterestExpenseMember2020-11-012021-07-310001090872us-gaap:InterestExpenseMember2019-11-012020-07-310001090872a:SegmentTotalMember2021-05-012021-07-310001090872a:SegmentTotalMember2020-05-012020-07-310001090872a:SegmentTotalMember2020-11-012021-07-310001090872a:SegmentTotalMember2019-11-012020-07-310001090872a:SegmentTotalMember2021-07-310001090872a:SegmentTotalMember2020-10-31
Table of Contents
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 10-Q
 
(MARK ONE) 
QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. 
For the quarterly period ended July 31, 2021 
OR 
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. 
For transition period from              to        
 Commission File Number: 001-15405
 AGILENT TECHNOLOGIES, INC.
(Exact Name of registrant as specified in its charter)
Delaware 77-0518772
(State or other jurisdiction of incorporation or organization)(IRS Employer Identification No.)
 
5301 Stevens Creek Blvd.,
Santa Clara, California 95051
(Address of principal executive offices)

Registrant’s telephone number, including area code: (800) 227-9770  

Securities registered pursuant to Section 12(b) of the Act:
Title of each ClassTrading SymbolName of each Exchange on which registered
Common Stock, $0.01 par valueANew York Stock Exchange
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.  Yes    No  
 Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).  Yes    No    
 Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and "emerging growth company" in Rule 12b-2 of the Exchange Act.
Large accelerated filer
Accelerated filer
Non-accelerated filer
Smaller reporting company
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.      
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).  Yes   No   

As of August 26, 2021, the registrant had 302,722,668 shares of common stock, $0.01 par value per share, outstanding.


Table of Contents
AGILENT TECHNOLOGIES, INC.
TABLE OF CONTENTS
 
   Page
Number
 
 
  
  
  
  
 
 
 
 
 
 
 
 
Item 6.
Exhibits
  

2

Table of Contents
PART I— FINANCIAL INFORMATION
 
ITEM 1. CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)
 
AGILENT TECHNOLOGIES, INC.
CONDENSED CONSOLIDATED STATEMENT OF OPERATIONS
(in millions, except per share amounts)
(Unaudited)
 
Three Months EndedNine Months Ended
 July 31,July 31,
 2021202020212020
Net revenue:    
Products$1,188 $932 $3,510 $2,878 
Services and other398 329 1,149 978 
Total net revenue1,586 1,261 4,659 3,856 
Costs and expenses:    
Cost of products521 422 1,534 1,293 
Cost of services and other213 170 618 514 
Total costs734 592 2,152 1,807 
Research and development113 92 325 393 
Selling, general and administrative403 347 1,230 1,109 
Total costs and expenses1,250 1,031 3,707 3,309 
Income from operations336 230 952 547 
Interest income 1 1 7 
Interest expense(21)(19)(60)(59)
Other income (expense), net12 7 19 64 
Income before taxes327 219 912 559 
Provision for income taxes63 20 144 62 
Net income$264 $199 $768 $497 
Net income per share:  
Basic$0.87 $0.64 $2.52 $1.61 
Diluted$0.86 $0.64 $2.50 $1.59 
Weighted average shares used in computing net income per share:    
Basic303 309 305 309 
Diluted306 312 307 312 
 
The accompanying notes are an integral part of these condensed consolidated financial statements.

3

Table of Contents
AGILENT TECHNOLOGIES, INC.
CONDENSED CONSOLIDATED STATEMENT OF COMPREHENSIVE INCOME (LOSS)
(in millions)
(Unaudited)

Three Months EndedNine Months Ended
 July 31,July 31,
 2021202020212020
Net income$264 $199 $768 $497 
Other comprehensive income (loss):
Unrealized gain (loss) on derivative instruments, net of tax expense (benefit) of $1, $(2), $(1) and $(2)
 (7)(4)(4)
Amounts reclassified into earnings related to derivative instruments, net of tax expense of $1, $0, $5 and $0
4 (1)14 (2)
Foreign currency translation, net of tax expense of $0, $0, $0 and $0
(17)60 27 20 
Net defined benefit pension cost and post retirement plan costs:
Change in actuarial net loss, net of tax expense of $3, $4, $11 and $9
11 10 32 28 
Change in net prior service benefit, net of tax expense (benefit) of $0, $(1), $0 and $(1)
  (1)(4)
Other comprehensive income (loss)(2)62 68 38 
Total comprehensive income$262 $261 $836 $535 


The accompanying notes are an integral part of these condensed consolidated financial statements.

4

Table of Contents
AGILENT TECHNOLOGIES, INC.
CONDENSED CONSOLIDATED BALANCE SHEET
(in millions, except par value and share amounts)
(Unaudited)
 July 31,
2021
October 31,
2020
ASSETS  
Current assets:  
Cash and cash equivalents$1,428 $1,441 
Accounts receivable, net1,122 1,038 
Inventory818 720 
Other current assets264 216 
Total current assets3,632 3,415 
Property, plant and equipment, net905 845 
Goodwill3,976 3,602 
Other intangible assets, net1,032 831 
Long-term investments204 158 
Other assets742 776 
Total assets$10,491 $9,627 
LIABILITIES AND EQUITY  
Current liabilities:  
Accounts payable$416 $354 
Employee compensation and benefits423 367 
Deferred revenue443 386 
Short-term debt130 75 
Other accrued liabilities312 285 
Total current liabilities1,724 1,467 
Long-term debt2,728 2,284 
Retirement and post-retirement benefits365 389 
Other long-term liabilities728 614 
Total liabilities5,545 4,754 
Commitments and contingencies (Note 8, 9 and 12)
Total equity:  
Stockholders’ equity:  
Preferred stock; $0.01 par value; 125 million shares authorized; none issued and outstanding
  
Common stock; $0.01 par value; 2 billion shares authorized; 303 million shares at July 31, 2021 and 306 million shares at October 31, 2020 issued and outstanding
3 3 
Additional paid-in-capital5,307 5,311 
 Retained earnings90 81 
Accumulated other comprehensive loss(454)(522)
Total stockholders' equity4,946 4,873 
Total liabilities and stockholders' equity$10,491 $9,627 

 
The accompanying notes are an integral part of these condensed consolidated financial statements.
5

Table of Contents
AGILENT TECHNOLOGIES, INC.
CONDENSED CONSOLIDATED STATEMENT OF CASH FLOWS
(in millions)
(Unaudited)
Nine Months Ended
 July 31,
 20212020
Cash flows from operating activities:
Net income$768 $497 
Adjustments to reconcile net income to net cash provided by operating activities:  
Depreciation and amortization237 232 
Share-based compensation88 63 
Deferred taxes41 (1)
Excess and obsolete inventory related charges21 18 
Loss on extinguishment of debt17  
Unrealized gain on equity securities, net(19)(26)
Asset impairment charges2 99 
Other non-cash expense, net1 6 
Changes in assets and liabilities:  
Accounts receivable(69)1 
Inventory(115)(86)
Accounts payable46 (35)
Employee compensation and benefits38 (32)
Other assets and liabilities(12)(192)
Net cash provided by operating activities1,044 544 
Cash flows from investing activities:  
Investments in property, plant and equipment(126)(92)
Proceeds from sale of property, plant and equipment 1 
Payment to acquire fair value investments(15)(20)
Payment in exchange for convertible note(2)(9)
Payment to acquire intangible assets(1) 
Acquisitions of businesses and intangible assets, net of cash acquired(546) 
Net cash used in investing activities(690)(120)
Cash flows from financing activities:  
Issuance of common stock under employee stock plans52 56 
Payment of taxes related to net share settlement of equity awards(74)(34)
Payment of dividends(177)(167)
Issuance of senior notes848 499 
Debt issuance costs(7)(4)
Proceeds from revolving credit facility 798 
Repayment of debt and revolving credit facility (1,413)
Repayment of senior notes(417) 
Proceeds from commercial paper1,492 240 
Repayment of commercial paper(1,437)(200)
Repayment of finance lease (4)
Treasury stock repurchases(652)(219)
Net cash used in financing activities(372)(448)
Effect of exchange rate movements6  
Net decrease in cash, cash equivalents and restricted cash(12)(24)
Cash, cash equivalents and restricted cash at beginning of period1,447 1,388 
Cash, cash equivalents and restricted cash at end of period$1,435 $1,364 
Supplemental cash flow information:
Income tax paid, net$164 $325 
Interest payments$53 $53 
The accompanying notes are an integral part of these condensed consolidated financial statements.
6

Table of Contents
AGILENT TECHNOLOGIES, INC.
CONDENSED CONSOLIDATED STATEMENT OF EQUITY
(in millions, except number of shares in thousands)
(Unaudited)
 Common Stock Accumulated
Other
Comprehensive
Loss
 
Three Months Ended July 31, 2021Number
of
Shares
Par
Value
Additional
Paid-in
Capital
Retained Earnings (Accumulated Deficit)Total Stockholders' Equity
Balance as of April 30, 2021303,403 $3 $5,271 $(12)$(452)$4,810 
Components of comprehensive income, net of tax:
Net income— — — 264 — 264 
Other comprehensive loss— — — — (2)(2)
Total comprehensive income     262 
Cash dividends declared ($0.194 per common share)
— — — (59)— (59)
Share-based awards issued, net of tax of $1
296 — 24 — — 24 
Repurchase of common stock(804)— (10)(103)— (113)
Share-based compensation— — 22 — — 22 
Balance as of July 31, 2021302,895 $3 $5,307 $90 $(454)$4,946 

 Common Stock Accumulated
Other
Comprehensive
Loss
 
Nine Months Ended July 31, 2021Number
of
Shares
Par
Value
Additional
Paid-in
Capital
Retained EarningsTotal Stockholders' Equity
Balance as of October 31, 2020306,198 $3 $5,311 $81 $(522)$4,873 
Components of comprehensive income, net of tax:
Net income— — — 768 — 768 
Other comprehensive income— — — — 68 68 
Total comprehensive income     836 
Cash dividends declared ($0.582 per common share)             
— — — (177)— (177)
Share-based awards issued, net of tax of $74
1,939 — (22)— — (22)
Repurchase of common stock(5,242)— (70)(582)— (652)
Share-based compensation— — 88 — — 88 
Balance as of July 31, 2021302,895 $3 $5,307 $90 $(454)$4,946 

The accompanying notes are an integral part of these condensed consolidated financial statements.

7

Table of Contents

AGILENT TECHNOLOGIES, INC.
CONDENSED CONSOLIDATED STATEMENT OF EQUITY
(in millions, except number of shares in thousands)
(Unaudited)
 Common Stock Accumulated
Other
Comprehensive
Loss
 
Three Months Ended July 31, 2020Number
of
Shares
Par
Value
Additional
Paid-in
Capital
Retained
Earnings
Total Stockholders' Equity
Balance as of April 30, 2020308,443 $3 $5,288 $15 $(538)$4,768 
Components of comprehensive income, net of tax:
Net income— — — 199 — 199 
Other comprehensive income— — — — 62 62 
Total comprehensive income     261 
Cash dividends declared ($0.18 per common share)             
— — — (56)— (56)
Share-based awards issued, net of tax of $1
497 — 22 — — 22 
Repurchase of common stock(362)— (5)(28)— (33)
Share-based compensation— — 19 — — 19 
Balance as of July 31, 2020308,578 $3 $5,324 $130 $(476)$4,981 

 Common Stock Accumulated
Other
Comprehensive
Loss
 
Nine Months Ended July 31, 2020Number
of
Shares
Par
Value
Additional
Paid-in
Capital
Retained Earnings (Accumulated Deficit)Total Stockholders' Equity
Balance as of October 31, 2019309,071 $3 $5,277 $(18)$(514)$4,748 
Components of comprehensive income, net of tax:
Net income— — — 497 — 497 
Other comprehensive income— — — — 38 38 
Total comprehensive income     535 
Cash dividends declared ($0.54 per common share)             
— — — (167)— (167)
Share-based awards issued, net of tax of $34
2,258 — 21 — — 21 
Repurchase of common stock(2,751)— (37)(182)— (219)
Share-based compensation— — 63 — — 63 
Balance as of July 31, 2020308,578 $3 $5,324 $130 $(476)$4,981 

The accompanying notes are an integral part of these condensed consolidated financial statements.
8

Table of Contents
AGILENT TECHNOLOGIES, INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(UNAUDITED)

1. OVERVIEW, BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
 
Overview. Agilent Technologies, Inc. ("we", "Agilent" or the "company"), incorporated in Delaware in May 1999, is a global leader in life sciences, diagnostics and applied chemical markets, providing application focused solutions that include instruments, software, services and consumables for the entire laboratory workflow.

Our fiscal year-end is October 31, and our fiscal quarters end on January 31, April 30 and July 31. Unless otherwise stated, these dates refer to our fiscal year and fiscal quarters.

Basis of Presentation. We have prepared the accompanying financial data for the three and nine months ended July 31, 2021 and 2020 pursuant to the rules and regulations of the U.S. Securities and Exchange Commission (“SEC”). Certain information and footnote disclosures normally included in financial statements prepared in accordance with generally accepted accounting principles (“GAAP”) in the U.S. have been condensed or omitted pursuant to such rules and regulations. The October 31, 2020 condensed balance sheet data was derived from audited financial statements but does not include all the disclosures required in audited financial statements by U.S. GAAP. The accompanying financial data and information should be read in conjunction with our Annual Report on Form 10-K for the fiscal year ended October 31, 2020.

In the opinion of management, the accompanying condensed consolidated financial statements contain all normal and recurring adjustments necessary for a fair statement of our condensed consolidated balance sheet as of July 31, 2021 and October 31, 2020, condensed consolidated statement of comprehensive income (loss) for the three and nine months ended July 31, 2021 and 2020, condensed consolidated statement of operations for the three and nine months ended July 31, 2021 and 2020, condensed consolidated statement of cash flows for the nine months ended July 31, 2021 and 2020 and condensed consolidated statement of equity for the three and nine months ended July 31, 2021 and 2020.

Use of Estimates. The preparation of condensed consolidated financial statements in accordance with GAAP in the U.S. requires management to make estimates and assumptions that affect the amounts reported in our condensed consolidated financial statements and accompanying notes. Management bases its estimates on historical experience and various other assumptions believed to be reasonable. Although these estimates are based on management’s best knowledge of current events and actions that may impact the company in the future, actual results may be different from the estimates. Our critical accounting policies are those that affect our financial statements materially and involve difficult, subjective or complex judgments by management. Those policies are revenue recognition, inventory valuation, retirement and post-retirement benefit plan assumptions, valuation of goodwill and purchased intangible assets and accounting for income taxes.

Restricted Cash and Restricted Cash Equivalents. Restricted cash and restricted cash equivalents are included with cash and cash equivalents when reconciling the beginning-of-period and end-of-period total amounts shown on the statement of cash flows. A reconciliation of cash, cash equivalents and restricted cash to the condensed consolidated balance sheet follows:
 July 31,October 31
 20212020
(in millions)
Cash and cash equivalents$1,428 $1,441 
Restricted cash included in other assets7 6 
Total cash, cash equivalents and restricted cash$1,435 $1,447 

Leases. As of July 31, 2021 and October 31, 2020, operating lease right-of-use assets where we are the lessee were $182 million and $175 million, respectively, and were included within other assets in the accompanying condensed consolidated balance sheet. The associated operating lease liabilities were $186 million and $178 million as of July 31, 2021 and October 31, 2020, respectively, and were included in other accrued liabilities and other long-term liabilities in the accompanying condensed consolidated balance sheet.

Variable Interest Entities. We make a determination upon entering into an arrangement whether an entity in which we have made an investment is considered a Variable Interest Entity (“VIE”). We evaluate our investments in privately held companies on an ongoing basis. We have determined that as of July 31, 2021 and October 31, 2020, there were no VIEs required to be consolidated in our consolidated financial statements because we do not have a controlling financial interest in
9

AGILENT TECHNOLOGIES, INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED) - (Continued)




any of the VIEs in which we have invested nor are we the primary beneficiary. We account for these investments under either the equity method or as equity investments without readily determinable fair value, depending on the circumstances. We periodically reassess whether we are the primary beneficiary of a VIE. The reassessment process considers whether we have acquired the power to direct the most significant activities of the VIE through changes in governing documents or other circumstances. We also reconsider whether entities previously determined not to be VIEs have become VIEs and vice-versa, based on changes in facts and circumstances including changes in contractual arrangements and capital structure.

As of July 31, 2021 and October 31, 2020, the total carrying value of investments and loans in privately held companies considered as VIEs was $70 million and $67 million respectively. The maximum exposure is equal to the carrying value because we do not have future funding commitments. The investments are included on the long-term investments line and the loans on the other current assets and other assets lines (depending upon tenure of loan) on the condensed consolidated balance sheet.

Fair Value of Financial Instruments. The carrying values of certain of our financial instruments including cash and cash equivalents, accounts receivable, accounts payable, accrued compensation and other accrued liabilities approximate fair value because of their short maturities. The fair value of long-term equity investments which are readily determinable, and which are not accounted under the equity method are reported at fair value using quoted market prices for those securities when available with gains and losses included in net income. The fair value of long-term equity investments which are not readily determinable, and which are not accounted under the equity method are reported at cost with adjustments for observable changes in prices or impairments included in net income. The fair value of our senior notes, calculated from quoted prices which are primarily Level 1 inputs under the accounting guidance fair value hierarchy exceeds the carrying value by approximately $136 million and $162 million as of July 31, 2021 and October 31, 2020, respectively. The fair value is greater than carrying value primarily due to decreased market interest rates. The fair value of foreign currency contracts used for hedging purposes is estimated internally by using inputs tied to active markets. These inputs (for example, interest rate yield curves, foreign exchange rates, and forward and spot prices for currencies) are observable in the market or can be corroborated by observable market data for substantially the full term of the assets or liabilities. See also Note 9, "Fair Value Measurements" for additional information on the fair value of financial instruments and contingent consideration.


 2. NEW ACCOUNTING PRONOUNCEMENTS

Recently Adopted Accounting Pronouncements
In June 2016, the Financial Accounting Standards Board ("FASB") issued new guidance to require a financial asset measured at amortized cost basis, such as accounts receivable, to be presented at the net amount expected to be collected based on relevant information about past events, including historical experience, current conditions, and reasonable and supportable forecasts that affect the collectability of the reported amount. During 2018 and 2019, the FASB issued additional guidance and clarification. On November 1, 2020, we adopted this guidance which did not have a material impact on our condensed consolidated financial statements.

In January 2017, the FASB issued new guidance that simplifies the measurement of goodwill impairment by eliminating the Step 2 requirement that an entity compute the implied fair value of goodwill based on the fair values of its assets and liabilities to measure impairment. Instead, goodwill impairment will be measured as the difference between the fair value of the reporting unit and the carrying value of the reporting unit. The standard also clarifies the treatment of the income tax effect of tax deductible goodwill when measuring goodwill impairment loss. On November 1, 2020, we adopted this guidance which did not have a material impact on our condensed consolidated financial statements.

In August 2018, the FASB issued updates to improve the disclosure requirements for fair value measurements in Topic 820, Fair Value Measurement which eliminates certain disclosure requirements and modifies others. On November 1, 2020, we adopted these amendments which did not have a material impact on our consolidated financial statements and disclosures. See Note 9, "Fair Value Measurements" for additional information on the fair value of financial instruments disclosures.

In December 2019, the FASB issued new guidance to simplify the accounting for income taxes. This guidance eliminates certain exceptions to existing guidance related to the approach for intraperiod tax allocation, the methodology for calculating income taxes in an interim period and the recognition of deferred tax liabilities for outside basis differences. The guidance also improves consistent application by clarifying and amending existing guidance related to aspects of the accounting for franchise taxes and enacted changes in tax laws or rates and clarifies the accounting for transactions that result in a step up in the tax basis of goodwill. On November 1, 2020, we early adopted this guidance which did not have a material impact on our condensed
10

AGILENT TECHNOLOGIES, INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED) - (Continued)




consolidated financial statements and disclosures.

In March 2020, the FASB issued an update for facilitation of the effects of reference rate reform on financial reporting. This update provides optional guidance for a limited period of time to ease the potential burden in accounting for (or recognizing the effects of) reference rate reform on financial reporting. The amendments in the guidance provide optional expedients and exceptions for applying generally accepted accounting principles to contracts, hedging relationships, and other transactions affected by reference rate reform if certain criteria are met. The amendments apply to contracts, hedging relationships, and other transactions that reference London Inter-bank Offered Rate ("LIBOR") or another reference rate expected to be discontinued because of reference rate reform. When elected, the optional expedients for contract modifications are applied consistently for all eligible contracts or eligible transactions within the relevant Topic or Industry Subtopic in the FASB's Accounting Standards Codification. The guidance was effective upon issuance and may generally be applied through December 31, 2022 to any new or amended contracts, hedging relationships, and other transactions that reference LIBOR. In January 2021, the FASB issued an update that provides supplemental guidance and clarification of the reference rate reform. The update provides additional optional guidance on the transition from LIBOR to include derivative instruments that use an interest rate for margining, discounting or contract price alignment. The standard will ease, if warranted, the requirements for accounting for the future effects of the rate reform. An entity may elect to apply the amendments prospectively through December 31, 2022. We continue to monitor the impact that the discontinuance of LIBOR or another reference rate will have on our contracts, hedging relationships and other transactions.

Accounting Pronouncements Not Yet Adopted
There were no additions to the new accounting pronouncements not yet adopted as described in our Annual Report on Form 10-K for the fiscal year ended October 31, 2020.

Other amendments to GAAP in the U.S. that have been issued by the FASB or other standards-setting bodies that do not require adoption until a future date are not expected to have a material impact on our condensed consolidated financial statements upon adoption.

3. REVENUE


The following table presents the company’s total revenue and segment revenue disaggregated by geographical region:
Three Months Ended July 31
20212020
Life Sciences and Applied MarketsAgilent CrossLab
Diagnostics and Genomics
TotalLife Sciences and Applied MarketsAgilent CrossLab
Diagnostics and Genomics
Total
(in millions)
Revenue by Region
Americas$226 $193 $187 $606 $174 $156 $121 $451 
Europe155 157 111 423 111 127 84 322 
Asia Pacific299 210 48 557 272 180 36 488 
Total$680 $560 $346 $1,586 $557 $463 $241 $1,261 
Nine Months Ended July 31
20212020
Life Sciences and Applied MarketsAgilent CrossLab
Diagnostics and Genomics
TotalLife Sciences and Applied MarketsAgilent CrossLab
Diagnostics and Genomics
Total
(in millions)
Revenue by Region
Americas$681 $559 $502 $1,742 $553 $484 $365 $1,402 
Europe500 458 317 1,275 389 391 268 1,048 
Asia Pacific895 611 136 1,642 779 507 120 1,406 
Total$2,076 $1,628 $955 $4,659 $1,721 $1,382 $753 $3,856 
11

AGILENT TECHNOLOGIES, INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED) - (Continued)





The following table presents the company’s total revenue disaggregated by end markets and by revenue type:
Three Months EndedNine Months Ended
July 31July 31
2021202020212020
(in millions)
Revenue by End Markets
Pharmaceutical and Biopharmaceutical$576 $440 $1,628 $1,263 
Chemical and Energy334 260 976 839 
Diagnostics and Clinical242 178 691 572 
Food143 123 449 367 
Academia and Government138 119 423 375 
Environmental and Forensics153 141 492 440 
Total$1,586 $1,261 $4,659 $3,856 
Revenue by Type
Instrumentation$640 $526 $1,953 $1,610 
Non-instrumentation and other946 735 2,706 2,246 
Total$1,586 $1,261 $4,659 $3,856 

Revenue by region is based on the ship to location of the customer. Revenue by end market is determined by the market indicator of the customer and by customer type. Instrumentation revenue includes sales from instruments, remarketed instruments and third-party products. Non-instrumentation and other revenue include sales from contract and per incident services, our companion diagnostics and our nucleic acid solutions businesses as well as sales from spare parts, consumables, reagents, vacuum pumps, subscriptions, software licenses and associated services.

Contract Balances

Contract Assets

Contract assets (unbilled accounts receivable) primarily relate to the company's right to consideration for work completed but not billed at the reporting date. The unbilled receivables are reclassified to trade receivables when billed to customers. Contract assets are generally classified as current assets and are included in "Accounts receivable, net" in the condensed consolidated balance sheet. The balances of contract assets as of July 31, 2021 and October 31, 2020 were $182 million and $153 million, respectively.

Contract Liabilities

The following table provides information about contract liabilities (deferred revenue) and the significant changes in the balances during the nine months ended July 31, 2021:
Contract
Liabilities
(in millions)